16.11.2016
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG: Formycon Makes Good Progress in First Nine Months of 2016
DGAP-News: Formycon AG / Key word(s): 9-month figures/Forecast
Formycon AG: Formycon Makes Good Progress in First Nine Months of 2016
16.11.2016 / 07:50
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release // November 16, 2016
Formycon Makes Good Progress in First Nine Months of 2016
- Advancing expansion and development of valuable pipeline
- Economic results in line with expectations
- Euro 20 million sales target for whole of 2016
Munich - In the first nine months of the 2016 financial year, the
biosimilars company Formycon has further advanced the development of its
drug candidates. Revenue from sales has primarily been generated through
the development of the two partnered biosimilar product candidates FYB201
and FYB203. At the same time, Formycon has also invested heavily in both of
its own development programs - FYB202 and FYB205 - thereby continuing its
successful economic path as planned. With a turnover of Euro 11.66 million,
the Formycon Group achieved an overall performance of Euro 11.82 million
after consideration of other operating income worth Euro 0.16 million. The
nine-month earnings before interest, taxes, depreciation and amortizations
(EBITDA) stood at Euro -2.06 million, with the operating result (EBIT)
amounting to Euro -2.58 million. The result for the period totaled Euro
-2.57 million.
As of September 30, 2016, the Formycon Group held liquid assets worth Euro
16 million. Including short-term receivables from deliveries and services
worth around Euro 3 million, Formycon had liquid assets of around Euro 19
million at its disposal. As a result, the company continues to maintain a
solid financial buffer which will enable it to advance the development of
its biosimilar candidates.
For the full year, Formycon continues to anticipate group revenues in the
range of Euro 20 million.
In the first three quarters of 2016, Formycon AG as the actual operational
unit achieved sales of Euro 8.72 million, while the overall performance
amounted to Euro 8.87 million. The EBITDA stood at Euro -2.30 million, the
EBIT at Euro -2.82 million and earnings at Euro -2.81 million. On the day
of review, Formycon employed 68 people.
Dr. Nicolas Combé, Director and CFO of Formycon, believes these results
confirm that the company remains on the right path: "With the planned
investments in our biosimilar projects, we are building up a valuable
pipeline and positioning ourselves as a leading independent developer for
biosimilars. Together with our licensing partners Santo Holding and Bioeq
IP AG, our goal is to be the first to offer high-quality follow-on drugs
after the expiry of patents on reference products. The progress this year
shows us that we are on the right track."
Formycon currently has four biosimilar projects in clinical and pre-
clinical development. The furthest-advanced is FYB201, a biosimilar
candidate of the ophthalmic drug Lucentis* (ranibizumab), for which
patients have been enrolling in a global clinical phase III since the start
of 2016 in collaboration with Bioeq IP AG. FYB201 is therefore the world's
only Lucentis biosimilar to be in the phase III licensing study, the final
stage of clinical development to gain marketing approval.
FYB203, which has been licensed out to Santo Holding (Deutschland) GmbH, is
a biosimilar candidate for Eylea** (aflibercept) which, like Lucentis(R),
is used to treat neovascular, age-related macular degeneration (nAMD) and
other serious eye conditions. Details of the FYB202 and FYB205 projects,
which have not yet been partnered and the rights to which are still fully
owned by Formycon, have so far not been published.
* Lucentis is a registered trademark of Genentech Inc.
**Eylea is a registered trademark of Regeneron Pharmaceuticals Inc.
About Formycon:
Formycon is a leading independent pure play developer of biosimilars and
has become a recognized innovator in this field. The company has extensive
experience in the development of complex biological molecules. Formycon's
specialist expertise allows the company to develop high-quality biosimilars
that meet the strict regulatory requirements of highly regulated markets
such as Europe and the United States. Formycon currently has four
biosimilars under development, of which two have been licensed out.
About biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have
revolutionized the treatment of serious diseases such as cancer, diabetes,
rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming
years, many of these biotech drugs will lose their patent protection - and
by 2020, medications with revenues of more than USD 100 billion will be off
patent. Biosimilars are follow-on versions of biopharmaceuticals, for which
exclusivity has expired. They are approved via stringent regulatory
pathways in highly regulated markets (such as EU, US, Japan, Canada,
Australia) based on proven similarity of the biosimilar with the originator
biopharmaceutical reference product. While the global market for
biosimilars is currently some USD 3.0 billion, industry experts expect this
figure to grow tenfold by the year 2025. In contrast to traditional generic
drugs, the development and production of biosimilars is highly complex and
requires specialized expertise.
Contact:
Thorsten Schüller
Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
phone +49 (0) 89 - 86 46 67 150
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This press release may contain forward-looking statements and information
which are based on our current expectations and certain assumptions.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, performance of the company, development of the products and the
estimates given here.
Such known and unknown risks and uncertainties comprise, among others, the
research and development, the regulatory approval process, the timing of
the actions of regulatory bodies and other governmental authorities,
clinical results, changes in laws and regulations, product quality, patient
safety, patent litigation, contractual risks and dependencies from third
parties. With respect to pipeline products, Formycon AG does not provide
any representation, warranties or any other guarantees that the products
will receive the necessary regulatory approvals or that they will prove to
be commercially exploitable and/or successful.
Formycon AG assumes no obligation to update these forward-looking
statements or to correct them in case of developments which differ from
those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an
offer to buy or subscribe for securities of Formycon AG. No public offering
of securities of Formycon AG will be made nor is a public offering
intended.
This document and the information contained therein may not be distributed
in or into the United States of America, Canada, Australia, Japan or any
other jurisdictions, in which such offer or such solicitation would be
prohibited. This document does not constitute an offer for the sale of
securities in the United States.
---------------------------------------------------------------------------
16.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Regulated Unofficial Market in Berlin, Tradegate Exchange;
Open Market (Entry Standard) in Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
521071 16.11.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB